{
    "N/R/U": null,
    "Applicant": "Argenx BV",
    "BLA Number": "761304",
    "Proprietary Name": "Vyvgart Hytrulo",
    "Proper Name": "efgartigimod alfa and hyaluronidase-qvfc",
    "BLA Type": "351(a)",
    "Strength": "1,008MG/5.6ML; 11,200UNITS/5.6ML (180MG/2,000UNITS/ML)",
    "Dosage Form": "Injection ",
    "Route of Administration": "Subcutaneous",
    "Product Presentation": "Single-Dose Vial",
    "Marketing Status": "Rx",
    "Licensure": "Licensed",
    "Approval Date": "June 20, 2023",
    "Ref. Product Proper Name": null,
    "Ref. Product Proprietary Name": null,
    "Supplement Number": null,
    "Submission Type": "Original",
    "License Number": "2217",
    "Product Number": "001",
    "Center": "CDER",
    "Date of First Licensure": null,
    "Exclusivity Expiration Date": null,
    "First Interchangeable Exclusivity Exp. Date": null,
    "Ref. Product Exclusivity Exp. Date": null,
    "Orphan Exclusivity Exp. Date": "June 21, 2031",
    "drug": [
        {
            "name": "efgartigimod alfa and hyaluronidase-qvfc",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15270"
        }
    ]
}